Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma / Facon, Thierry; Kumar, Shaji; Plesner, Torben; Orlowski, Robert Z; Moreau, Philippe; Bahlis, Nizar; Basu, Supratik; Nahi, Hareth; Hulin, Cyrille; Quach, Hang; Goldschmidt, Hartmut; O'Dwyer, Michael; Perrot, Aurore; Venner, Christopher P; Weisel, Katja; Mace, Joseph R; Raje, Noopur; Attal, Michel; Tiab, Mourad; Macro, Margaret; Frenzel, Laurent; Leleu, Xavier; Ahmadi, Tahamtan; Chiu, Christopher; Wang, Jianping; Van Rampelbergh, Rian; Uhlar, Clarissa M; Kobos, Rachel; Qi, Ming; Usmani, Saad Z, Bosi A. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - STAMPA. - 380:(2019), pp. 2104-2115-2115. [10.1056/NEJMoa1817249]
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Bosi AMembro del Collaboration Group
2019
Abstract
Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
